Abbott posted a 14.5% increase in reported sales and 7.0% comparable sales growth for Q3 2026, with GAAP diluted EPS of $0.53 and adjusted EPS of $1.42. The company expanded its portfolio with FDA approvals for innovative products like the Libre Duo glucose-ketone sensor and the TactiFlex Duo ablation catheter. Abbott reaffirmed its full-year 2026 adjusted EPS guidance range of $5.50 to $5.55 and projects approximately 6.0% comparable sales growth for the year. Strong performance across diagnostics, medical devices, nutrition, and pharmaceuticals positions Abbott for sustained growth.
Abbott Laboratories (ABT) trades at USD 98.50 on Pluang as of Oct 21, 2026 18:42 WIB, down 4.09% for the day. The stock shows a dividend yield of 2.46% and a market cap of $177.28 billion. Despite the recent price drop, Pluang investors hold the stock for an average of 96 days, with 67% currently buying and 33% selling.
